Background: The demand for producing recombinant therapeutic proteins by mammalian cell lines, such as Chinese hamster ovary (CHO) cells, continues to grow. Significant achievements in process optimization including development of cell culture strategies for largescale and cost-effective production have been made. Fetal bovine serum (FBS) is an often essential growth supplement and yet most cos...
